TrialCancer discovery2021

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.

Otto Metzger Filho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.